Jan Volavka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4396532/publications.pdf

Version: 2024-02-01

		30070	32842
189	11,017	54	100
papers	citations	h-index	g-index
196	196	196	7485
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Dissociation, Cognitive Reflection and Health Literacy Have a Modest Effect on Belief in Conspiracy Theories about COVID-19. International Journal of Environmental Research and Public Health, 2021, 18, 5065.	2.6	23
2	Serious physical assault and subsequent risk for rehospitalization in individuals with severe mental illness: a nationwide, register-based retrospective cohort study. Annals of General Psychiatry, 2021, 20, 44.	2.7	3
3	Specific Anti-hostility Effects of Atypical Antipsychotics in Persons with Schizophrenia: From Clozapine to Cariprazine. Harvard Review of Psychiatry, 2021, 29, 20-34.	2.1	11
4	Willingness to Vaccinate Against COVID-19: The Role of Health Locus of Control and Conspiracy Theories. Frontiers in Psychology, 2021, 12, 717960.	2.1	8
5	Deconstructing violence in acutely exacerbating psychotic patients. CNS Spectrums, 2020, , 1-5.	1.2	5
6	Psychopharmacology of Violent Behavior Among People with Severe Mental Disorders. Comprehensive Approach To Psychiatry, 2020, , 253-268.	1.0	0
7	Very long-term outcome of schizophrenia. International Journal of Clinical Practice, 2018, 72, e13094.	1.7	24
8	Understanding the Risk of Treatment Failure After Discontinuation of Long-Term Antipsychotic Treatment. American Journal of Psychiatry, 2018, 175, 908-909.	7.2	0
9	Measurement of agitation and aggression in adult and aged neuropsychiatric patients: review of definitions and frequently used measurement scales. CNS Spectrums, 2017, 22, 407-414.	1.2	19
10	Triggering Violence in Psychosis. JAMA Psychiatry, 2016, 73, 769.	11.0	11
10	Triggering Violence in Psychosis. JAMA Psychiatry, 2016, 73, 769. Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies. European Psychiatry, 2016, 31, 13-19.	11.0	11
	Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies.		
11	Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies. European Psychiatry, 2016, 31, 13-19. Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST	0.2	17
11 12	Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies. European Psychiatry, 2016, 31, 13-19. Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies. European Neuropsychopharmacology, 2015, 25, 1158-1166. Preventing Violence in Patients with Schizophrenia. Current Treatment Options in Psychiatry, 2015, 2,	0.2	17 84
11 12 13	Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies. European Psychiatry, 2016, 31, 13-19. Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies. European Neuropsychopharmacology, 2015, 25, 1158-1166. Preventing Violence in Patients with Schizophrenia. Current Treatment Options in Psychiatry, 2015, 2, 182-191.	0.2	17 84 4
11 12 13	Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies. European Psychiatry, 2016, 31, 13-19. Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies. European Neuropsychopharmacology, 2015, 25, 1158-1166. Preventing Violence in Patients with Schizophrenia. Current Treatment Options in Psychiatry, 2015, 2, 182-191. Aggression in Psychoses. Advances in Psychiatry, 2014, 2014, 1-20. Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical	0.2 0.7 1.9	17 84 4 10
11 12 13 14	Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies. European Psychiatry, 2016, 31, 13-19. Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies. European Neuropsychopharmacology, 2015, 25, 1158-1166. Preventing Violence in Patients with Schizophrenia. Current Treatment Options in Psychiatry, 2015, 2, 182-191. Aggression in Psychoses. Advances in Psychiatry, 2014, 2014, 1-20. Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. CNS Spectrums, 2014, 19, 374-381. Review: 15 antipsychotic drugs are more effective than placebo for the treatment of schizophrenia,	0.2 0.7 1.9 0.4	17 84 4 10

#	Article	IF	CITATIONS
19	Why is ITAREPS successful?. Schizophrenia Research, 2014, 152, 530.	2.0	O
20	Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study – ADDENDUM. CNS Spectrums, 2014, 19, 466-466.	1.2	4
21	Insight and Hostility as Predictors and Correlates of Nonadherence in the European First Episode Schizophrenia Trial. Journal of Clinical Psychopharmacology, 2013, 33, 258-261.	1.4	14
22	Violence in schizophrenia and bipolar disorder. Psychiatria Danubina, 2013, 25, 24-33.	0.4	96
23	Clozapine is gold standard, but questions remain. International Journal of Neuropsychopharmacology, 2012, 15, 1201-1204.	2.1	7
24	Teaching Critical Appraisal of Articles on Psychopharmacology. Academic Psychiatry, 2012, 36, 114-7.	0.9	6
25	A Meta-Analysis of the Val158Met COMT Polymorphism and Violent Behavior in Schizophrenia. PLoS ONE, 2012, 7, e43423.	2.5	42
26	Mental disorder and violence: is there a relationship beyond substance use?. Social Psychiatry and Psychiatric Epidemiology, 2012, 47, 487-503.	3.1	265
27	Pharmacological Management of Acute and Persistent Aggression in Forensic Psychiatry Settings. CNS Drugs, 2011, 25, 1009-1021.	5.9	40
28	Pathways to Aggression in Schizophrenia Affect Results of Treatment. Schizophrenia Bulletin, 2011, 37, 921-929.	4.3	154
29	Differential regulation of catechol-O-methyltransferase expression in a mouse model of aggression. Brain Structure and Function, 2011, 216, 347-356.	2.3	11
30	Genetic interactions in the adrenergic system genes: analysis of antipsychoticâ€induced weight gain. Human Psychopharmacology, 2011, 26, 386-391.	1.5	10
31	Violent Crime, Epilepsy, and Traumatic Brain Injury. PLoS Medicine, 2011, 8, e1001148.	8.4	8
32	Efficacy of Antipsychotic Drugs Against Hostility in the European First-Episode Schizophrenia Trial (EUFEST). Journal of Clinical Psychiatry, 2011, 72, 955-961.	2.2	43
33	Violent Behavior in Mental Illness: The Role of Substance Abuse. JAMA - Journal of the American Medical Association, 2010, 304, 563.	7.4	56
34	Psychiatric patients with histories of aggression and crime five years after discharge from a cognitive-behavioral program. Journal of Forensic Psychiatry and Psychology, 2010, 21, 167-188.	1.0	24
35	Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone. Neuropsychiatric Disease and Treatment, 2009, 5, 47.	2.2	37
36	Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opinion on Pharmacotherapy, 2009, 10, 1917-1928.	1.8	69

#	Article	IF	CITATIONS
37	Staff and Patient Views of the Reasons for Aggressive Incidents: A Prospective, Incident-Based Study. Psychiatric Quarterly, 2009, 80, 167-172.	2.1	19
38	A Randomized, Placebo-Controlled Study of Memantine as Adjunctive Treatment in Patients with Schizophrenia. Neuropsychopharmacology, 2009, 34, 1322-1329.	5 . 4	155
39	Medication Nonadherence and Treatment Outcome in Patients With Schizophrenia or Schizoaffective Disorder With Suboptimal Prior Response. Journal of Clinical Psychiatry, 2009, 70, 990-996.	2.2	139
40	All Antipsychotics Are Equal, but Some Are More Equal Than Others. Journal of Clinical Psychiatry, 2009, 70, 429-430.	2.2	1
41	Methodological Structure for Aggression Research. Psychiatric Quarterly, 2008, 79, 293-300.	2.1	7
42	Are all antipsychotics equal?. Lancet, The, 2008, 372, 201-202.	13.7	13
43	Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. British Journal of Psychiatry, 2008, 193, 37-43.	2.8	171
44	Standard and Higher Dose of Olanzapine in Patients With Schizophrenia or Schizoaffective Disorder. Journal of Clinical Psychopharmacology, 2008, 28, 392-400.	1.4	89
45	Ambulatory Electroconvulsive Therapy. Review of Russian Translation of a 1996 Report of an Association for Convulsive Therapy Task Force. Journal of ECT, 2007, 23, 128-129.	0.6	0
46	Lamotrigine as Add-On Therapy in Schizophrenia. Journal of Clinical Psychopharmacology, 2007, 27, 582-589.	1.4	112
47	Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. International Clinical Psychopharmacology, 2007, 22, 356-362.	1.7	43
48	HTR2C haplotypes and antipsychoticsâ€induced weight gain: Xâ€linked multimarker analysis. Human Psychopharmacology, 2007, 22, 463-467.	1.5	39
49	Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ: British Medical Journal, 2006, 333, 224.	2.3	317
50	Catechol-O-methyltransferase and Monoamine Oxidase-A Polymorphisms and Treatment Response to Typical and Atypical Neuroleptics. Journal of Clinical Psychopharmacology, 2006, 26, 338-340.	1.4	5
51	Video Recording in the Assessment of Violent Incidents in Psychiatric Hospitals. Journal of Psychiatric Practice, 2006, 12, 58-63.	0.7	9
52	Aggression and Quantitative MRI Measures of Caudate in Patients With Chronic Schizophrenia or Schizoaffective Disorder. Journal of Neuropsychiatry and Clinical Neurosciences, 2006, 18, 509-515.	1.8	38
53	Family and case–control association study of the tumor necrosis factor-alpha (TNF-α) gene with schizophrenia and response to antipsychotic medication. Psychopharmacology, 2006, 188, 171-182.	3.1	48
54	The relationship between history of violent and criminal behavior and recognition of facial expression of emotions in men with schizophrenia and schizoaffective disorder. Aggressive Behavior, 2006, 32, 187-194.	2.4	69

#	Article	lF	CITATIONS
55	Efficacy of Ziprasidone Against Hostility in Schizophrenia. Journal of Clinical Psychiatry, 2006, 67, 638-642.	2.2	35
56	Eficacia de la monoterapia de clozapina, olanzapina, quetiapina, risperidona y haloperidol en la reducciÃ ³ n del comportamiento hostil y agresivo en pacientes ambulatorios tratados por esquizofrenia: un estudio naturalista prospectivo (IC-SOHO). European Psychiatry (Ed Española), 2006, 13, 70-76.	0.0	0
57	Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder. Psychiatry Research - Neuroimaging, 2005, 140, 133-145.	1.8	79
58	Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder. Journal of Psychiatric Research, 2005, 39, 109-115.	3.1	65
59	Suggestive association between the C825T polymorphism of the G-protein \hat{I}^2 3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia. European Neuropsychopharmacology, 2005, 15, 525-531.	0.7	59
60	Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO). European Psychiatry, 2005, 20, 403-408.	0.2	47
61	The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neuroscience Letters, 2005, 379, 81-89.	2.1	93
62	Identification of a naturally occurring 21bp deletion in alpha2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment. Pharmacological Research, 2005, 51, 381-384.	7.1	8
63	Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation. Schizophrenia Research, 2005, 76, 127-129.	2.0	6
64	Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Journal of Clinical Psychiatry, 2005, 66, 1073-1074.	2.2	14
65	Efficacy of Aripiprazole Against Hostility in Schizophrenia and Schizoaffective Disorder. Journal of Clinical Psychiatry, 2005, 66, 1362-1366.	2.2	34
66	Screaming and Physical Aggression in Nursing Homes. American Journal of Geriatric Psychiatry, 2005, 13, 539-540.	1.2	1
67	The promise of atypical antipsychotics. Postgraduate Medicine, 2004, 116, 49-63.	2.0	20
68	Olanzapine vs Haloperidol for Treatment of Schizophrenia. JAMA - Journal of the American Medical Association, 2004, 291, 1064.	7.4	1
69	Course of Patients With Histories of Aggression and Crime After Discharge From a Cognitive-Behavioral Program. Psychiatric Services, 2004, 55, 654-659.	2.0	41
70	Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes: Response to consensus statement. Diabetes Care, 2004, 27, 2087-2088.	8.6	15
71	The Catechol-O-Methyltransferase Polymorphism: Relations to the Tonic–Phasic Dopamine Hypothesis and Neuropsychiatric Phenotypes. Neuropsychopharmacology, 2004, 29, 1943-1961.	5.4	704
72	COMT158 polymorphism and hostility. American Journal of Medical Genetics Part A, 2004, 127B, 28-29.	2.4	28

#	Article	IF	Citations
73	CatecholO-Methyltransferase Val158Met Polymorphism in Schizophrenia: Differential Effects of Val and Met Alleles on Cognitive Stability and Flexibility. American Journal of Psychiatry, 2004, 161, 359-361.	7.2	213
74	Overt Aggression and Psychotic Symptoms in Patients With Schizophrenia Treated With Clozapine, Olanzapine, Risperidone, or Haloperidol. Journal of Clinical Psychopharmacology, 2004, 24, 225-228.	1.4	160
75	Overt Aggression and Psychotic Symptoms in Patients With Schizophrenia Treated With Clozapine, Olanzapine, Risperidone, or Haloperidol. Journal of Clinical Psychopharmacology, 2004, 24, 1-4.	1.4	9
76	Catecholamines and Aggression: The Role of COMT and MAO Polymorphisms. Annals of the New York Academy of Sciences, 2004, 1036, 393-398.	3.8	123
77	Prolactin Levels in Schizophrenia and Schizoaffective Disorder Patients Treated With Clozapine, Olanzapine, Risperidone, or Haloperidol. Journal of Clinical Psychiatry, 2004, 65, 57-61.	2.2	151
78	Effects of Atypical Antipsychotics on the Syndromal Profile in Treatment-Resistant Schizophrenia. Journal of Clinical Psychiatry, 2004, 65, 551-556.	2.2	59
79	Changes in Glucose and Cholesterol Levels in Patients With Schizophrenia Treated With Typical or Atypical Antipsychotics. American Journal of Psychiatry, 2003, 160, 290-296.	7.2	450
80	Characteristics of Assaultive Behavior Among Psychiatric Inpatients. Psychiatric Services, 2003, 54, 1012-1016.	2.0	121
81	Placebo or Active Control Trials of Antipsychotic Drugs?. Archives of General Psychiatry, 2003, 60, 458.	12.3	52
82	Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder. American Journal of Psychiatry, 2002, 159, 255-262.	7.2	377
83	Neurocognitive Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol in Patients With Chronic Schizophrenia or Schizoaffective Disorder. American Journal of Psychiatry, 2002, 159, 1018-1028.	7.2	493
84	Managing Treatment-Resistant Schizophrenia: Evidence from Randomized Clinical Trials. Journal of Psychiatric Practice, 2002, 8, 205-215.	0.7	30
85	Antipsychotic-Induced Weight Gain and Therapeutic Response: A Differential Association. Journal of Clinical Psychopharmacology, 2002, 22, 244-251.	1.4	149
86	Frontal white matter microstructure, aggression, and impulsivity in men with schizophrenia: a preliminary study. Biological Psychiatry, 2002, 52, 9-14.	1.3	204
87	Neurocognitive correlates of the COMT Val158Met polymorphism in chronic schizophrenia. Biological Psychiatry, 2002, 52, 701-707.	1.3	304
88	Optimal Dosing of Atypical Antipsychotics in Adults: A Review of the Current Evidence. Harvard Review of Psychiatry, 2002, 10, 280-291.	2.1	78
89	Atypical antipsychotics: revolutionary or incremental advance?. Expert Review of Neurotherapeutics, 2002, 2, 69-88.	2.8	22
90	Risk for Individuals With Schizophrenia Who Are Living in the Community. Psychiatric Services, 2002, 53, 484-485.	2.0	4

#	Article	IF	CITATIONS
91	Olanzapine in Refractory Schizophrenia After Failure of Typical or Atypical Antipsychotic Treatment. Journal of Clinical Psychiatry, 2002, 63, 931-935.	2.2	54
92	Dr. Bilder and Colleagues Reply. American Journal of Psychiatry, 2002, 159, 2118-a-2119.	7.2	0
93	Haloperidol Blood Levels in Acute Mania With Psychosis. Journal of Clinical Psychopharmacology, 2001, 21, 445-447.	1.4	3
94	Olanzapine for Schizophrenia Refractory to Typical and Atypical Antipsychotics: An Open-Label, Prospective Trial. Journal of Clinical Psychopharmacology, 2001, 21, 448-453.	1.4	31
95	Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol on Hostility Among Patients With Schizophrenia. Psychiatric Services, 2001, 52, 1510-1514.	2.0	177
96	Antiaggressive Effect of Quetiapine in a Patient With Schizoaffective Disorder. Journal of Clinical Psychiatry, 2001, 62, 901.	2.2	11
97	An association between a polymorphism of the tryptophan hydroxylase gene and aggression in schizophrenia and schizoaffective disorder. Psychiatric Genetics, 2000, 10, 109-115.	1.1	41
98	Suicidal behavior in patients with schizophrenia is related to COMT polymorphism. Psychiatric Genetics, 2000, 10, 117-124.	1.1	96
99	Lack of association between the functional variant of the catechol-o-methyltransferase (COMT) gene and early-onset alcoholism associated with severe antisocial behavior. American Journal of Medical Genetics Part A, 2000, 96, 348-352.	2.4	60
100	IQ scores of treatment-resistant schizophrenia patients before and after the onset of the illness. Schizophrenia Research, 2000, 46, 203-207.	2.0	24
101	Pharmacological Interventions for Preventing Violence Among the Mentally III with Co-Occurring Personality Disorders. , 2000, , 193-209.		2
102	High-Dose Treatment With Haloperidol: The Effect of Dose Reduction. Journal of Clinical Psychopharmacology, 2000, 20, 252-256.	1.4	25
103	Management of Violence in Schizophrenia. Psychiatric Annals, 2000, 30, 41-52.	0.1	18
104	The Neurobiology of Violence. Journal of Neuropsychiatry and Clinical Neurosciences, 1999, 11, 307-314.	1.8	152
105	Association between the functional variant of the catechol-O-methyltransferase (COMT) gene and type 1 alcoholism. Molecular Psychiatry, 1999, 4, 286-289.	7.9	173
106	Association between low activity serotonin transporter promoter genotype and early onset alcoholism with habitual impulsive violent behavior. Molecular Psychiatry, 1999, 4, 385-388.	7.9	222
107	VIOLENT PATIENTS IN THE EMERGENCY SETTING. Psychiatric Clinics of North America, 1999, 22, 789-801.	1.3	49
108	Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns. Schizophrenia Research, 1999, 35, S23-S33.	2.0	52

#	Article	IF	CITATIONS
109	Violence in Schizophrenia. Journal of Psychiatric Practice, 1999, 5, 326-335.	0.7	4
110	Psychopathy and Violent Behavior Among Patients With Schizophrenia or Schizoaffective Disorder. Psychiatric Services, 1999, 50, 787-792.	2.0	127
111	Violence in the Mentally Ill: Questions Remain. Archives of General Psychiatry, 1999, 56, 193.	12.3	4
112	Schizophrenia: violence and comorbidity. Current Opinion in Psychiatry, 1999, 12, 47-51.	6.3	14
113	Acute Mania: Haloperidol Dose and Augmentation With Lithium or Lorazepam. Journal of Clinical Psychopharmacology, 1999, 19, 500-505.	1.4	42
114	Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder. Psychiatry Research, 1998, 81, 51-55.	3.3	16
115	Hypothesis testing: Is clozapine's superior efficacy dependent on moderate D2 receptor occupancy?. Biological Psychiatry, 1998, 43, 79-83.	1.3	13
116	History of violent behaviour and schizophrenia in different cultures. British Journal of Psychiatry, 1997, 171, 9-14.	2.8	105
117	Analysis of a functional catechol-O-methyltransferase gene polymorphism in schizophrenia: evidence for association with aggressive and antisocial behavior. Psychiatry Research, 1997, 69, 71-77.	3.3	203
118	Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes. Psychiatry Research, 1997, 71, 19-26.	3.3	39
119	Genetic and Neurochemical Correlates of Violence. Psychiatric Annals, 1997, 27, 679-682.	0.1	3
120	Psychopharmacology of Violence: Part I: Assessment and Acute Treatment. Psychiatric Annals, 1997, 27, 691-695.	0.1	14
121	Psychopharmacology of Violence: Part II: Beyond the Acute Episode. Psychiatric Annals, 1997, 27, 696-703.	0.1	18
122	Dimensions of the brief psychiatric rating scale: An examination of stability during haloperidol treatment. Comprehensive Psychiatry, 1996, 37, 205-215.	3.1	25
123	The Electroencephalogram After Alcohol Administration in High-Risk Men and the Development of Alcohol Use Disorders 10 Years Later. Archives of General Psychiatry, 1996, 53, 258.	12.3	118
124	Placebo Reconsidered. Canadian Journal of Psychiatry, 1995, 40, 426-427.	1.9	0
125	Plasma Haloperidol Levels and Clinical Effects in Schizophrenia and Schizoaffective Disorder. Archives of General Psychiatry, 1995, 52, 837.	12.3	48
126	Serotonin in violent patients with schizophrenia. Psychiatry Research, 1995, 59, 161-163.	3.3	13

#	Article	IF	CITATIONS
127	Effect of Risperidone on Hostility in Schizophrenia. Journal of Clinical Psychopharmacology, 1995, 15, 243-249.	1.4	119
128	BMY 14802, a Sigma Receptor Ligand for the Treatment of Schizophrenia. Neuropsychopharmacology, 1994, 10, 37-40.	5.4	66
129	Does the change of psychopathology during the placebo period predict the response to subsequent treatment with active medication?. Psychiatry Research, 1994, 52, 107-114.	3.3	3
130	Quantitative Electroencephalogram Examination of Effects of Risperidone in Schizophrenic Patients. Journal of Clinical Psychopharmacology, 1993, 13, 332???342.	1.4	43
131	Clozapine Effects on Hostility and Aggression in Schizophrenia. Journal of Clinical Psychopharmacology, 1993, 13, 287???288.	1.4	76
132	Pharmacoepidemiology of Clozapine in 202 Inpatients with Schizophrenia. Annals of Pharmacotherapy, 1993, 27, 1262-1269.	1.9	42
133	Haloperidol Blood Levels and Clinical Effects. Archives of General Psychiatry, 1992, 49, 354.	12.3	114
134	Brief Pulse ECT in Melancholia. Journal of Nervous and Mental Disease, 1992, 180, 55-57.	1.0	6
135	Are Extrapyramidal Symptoms Necessary for Antipsychotic Activity???? Reply. Journal of Clinical Psychopharmacology, 1992, 12, 65.	1.4	0
136	Inhibition of pyruvate dehydrogenase complex by antipsychotic drugs. Biological Psychiatry, 1992, 31, 99-100.	1.3	0
137	Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve. Psychiatry Research, 1992, 42, 129-144.	3.3	31
138	Psychobiology of the Violent Offender. Journal of Forensic Sciences, 1992, 37, 237-251.	1.6	25
139	HIV seroprevalence and risk behaviors in psychiatric inpatients. Psychiatry Research, 1991, 39, 109-114.	3.3	78
140	Relationship between the brief psychiatric rating scale and the scale for the assessment of negative symptoms: A study of their correlation and redundancy. Psychiatry Research, 1991, 36, 129-139.	3.3	40
141	Pretreatment EEG predicts short-term response to haloperidol treatment. Biological Psychiatry, 1991, 30, 927-942.	1.3	51
142	Validity of Self-Reports of Criminal Activity in Psychiatric Inpatients. Journal of Nervous and Mental Disease, 1990, 178, 48-51.	1.0	14
143	Dr. Krakowski and Associates Reply. American Journal of Psychiatry, 1990, 147, 1384-1385.	7.2	0
144	Tryptophan treatment of aggressive psychiatric inpatients. Biological Psychiatry, 1990, 28, 728-732.	1.3	60

#	Article	IF	Citations
145	The measurement of subjective experience in schizophrenia: The subjective deficit syndrome scale. Comprehensive Psychiatry, 1990, 31, 216-226.	3.1	63
146	Inpatient violence: Trait and state. Journal of Psychiatric Research, 1989, 23, 57-64.	3.1	32
147	Lithium and cholinomimetics. Biological Psychiatry, 1989, 26, 650-651.	1.3	0
148	Schizophrenia and violence. Psychological Medicine, 1989, 19, 559-562.	4.5	27
149	Pattern reversal visual evoked potentials after alcohol administration among men at risk for alcoholism. Psychiatry Research, 1988, 26, 191-202.	3.3	7
150	Predicting Assaultiveness in Psychiatric Inpatients: A Pilot Study. Psychiatric Services, 1988, 39, 429-434.	2.0	33
151	Underreporting of Physical Assaults in Schizophrenic Inpatients. Journal of Nervous and Mental Disease, 1988, 176, 507-509.	1.0	26
152	Prediction of Violence in Psychiatric Inpatients. , 1988, , 223-245.		8
153	Review of Haloperidol Blood Level and Clinical Response. Journal of Clinical Psychopharmacology, 1987, 7, 25???30.	1.4	46
154	Concurrent lithium administration results in higher haloperidol levels in brain and plasma of guinea pigs. Psychiatry Research, 1987, 20, 313-316.	3.3	13
155	Minor physical anomalies in violent adult inpatients. Biological Psychiatry, 1987, 22, 1166-1168.	1.3	2
156	Electroencephalogram among criminals. , 1987, , 137-145.		10
157	Multiple-dose pharmacokinetics of clozapine in patients. Pharmaceutical Research, 1987, 04, 402-405.	3.5	81
158	Psychopathology and violence: A review of literature. Comprehensive Psychiatry, 1986, 27, 131-148.	3.1	156
159	Lithium and lecithin in tardive dyskinesia: An update. Psychiatry Research, 1986, 19, 101-104.	3.3	9
160	Clomipramine and imipramine in obsessive-compulsive disorder. Psychiatry Research, 1985, 14, 85-93.	3.3	112
161	Late-onset schizophrenia: A review. Comprehensive Psychiatry, 1985, 26, 148-156.	3.1	24
162	The EEG in Persons at Risk for Alcoholism. , 1985, 3, 21-36.		24

#	Article	IF	Citations
163	A Prospective Study of Alcoholism: Electroencephalographic Findings. , 1984, , 125-145.		7
164	Short-lived effect of (des-tyr)-gamma-endorphin in schizophrenia. Psychiatry Research, 1983, 10, 243-252.	3.3	17
165	Naloxone, tardive dyskinesia, and endogenous beta-endorphin. Psychiatry Research, 1982, 7, 321-324.	3.3	15
166	NALOXONE AND NALTREXONE IN MENTAL ILLNESS AND TARDIVE DYSKINESIA. Annals of the New York Academy of Sciences, 1982, 398, 97-102.	3.8	17
167	Electroencephalograms in Children of Alcoholic Fathers. Psychophysiology, 1982, 19, 404-407.	2.4	149
168	Effects of caffeine on resting EEG and response to sine wave modulated light. Electroencephalography and Clinical Neurophysiology, 1981, 51, 470-476.	0.3	26
169	Action of Naloxone and Naltrexone in Different Types of Psychoses. Modern Problems of Pharmacopsychiatry, 1981, 17, 202-212.	2.5	9
170	Effect of piracetam on EEG spectra of boys with learning disorders. Psychopharmacology, 1981, 72, 185-188.	3.1	19
171	Short-term hormonal effects of naloxone in man. Psychoneuroendocrinology, 1980, 5, 225-234.	2.7	104
172	Electroencephalographic and other effects of naloxone in normal men Life Sciences, 1979, 25, 1267-1272.	4.3	28
173	Profile of Mood States: The Factors and Their Physiological Correlates. Journal of Nervous and Mental Disease, 1979, 167, 612-614.	1.0	115
174	Drs. Volavka and Mallya Reply. American Journal of Psychiatry, 1979, 136, 1229-1229.	7.2	0
175	METHADONE DOSE, PLASMA LEVEL, AND CROSS-TOLERANCE TO HEROIN IN MAN. Journal of Nervous and Mental Disease, 1978, 166, 104-109.	1.0	19
176	Electroencephalograms of XYY and XXY Men. British Journal of Psychiatry, 1977, 130, 43-47.	2.8	19
177	Understanding EEG: An Introduction to Electroencephalography. American Journal of Psychiatry, 1977, 134, 1062-1062.	7.2	0
178	EEG spectra in XYY and XXY men. Electroencephalography and Clinical Neurophysiology, 1977, 43, 798-801.	0.3	14
179	Naloxone in chronic schizophrenia. Science, 1977, 196, 1227-1228.	12.6	120
180	ACTH 4–10: a Study of Toxicological and Behavioral Effects in an Aging Sample. Neuropsychobiology, 1976, 2, 350-360.	1.9	12

#	Article	IF	CITATIONS
181	Effects of L-alpha-acetylmethadol (LAAM) and Methadone on Human EEG. Clinical EEG (electroencephalography), 1976, 7, 198-202.	0.9	0
182	Short-Term Effects of Heroin in Man. Archives of General Psychiatry, 1974, 30, 677.	12.3	16
183	Marijuana, hashish and tetrahydrocannabinol-î"-9: effects on EEG, heart rate and mood. Journal of Psychiatric Research, 1974, 10, 159.	3.1	0
184	EEG seizure patterns during multiple unilateral and bilateral ECT. Comprehensive Psychiatry, 1973, 14, 25-28.	3.1	29
185	EEG and clinical change after bilateral and unilateral electroconvulsive therapy. Electroencephalography and Clinical Neurophysiology, 1972, 32, 631-639.	0.3	39
186	MARIJUANA, EEG, AND BEHAVIOR. Annals of the New York Academy of Sciences, 1971, 191, 206-215.	3.8	31
187	Opiates and Antagonists. , 1971, , 452-467.		10
188	Effect of nitrazepam, amylobarbitone sodium and placebo on the electroencephalogram of normal subjects. Psychopharmacology, 1969, 14, 178-183.	3.1	8
189	Psychopharmacology of Violence. , 0, , 645-653.		0